Académique Documents
Professionnel Documents
Culture Documents
breast cancer
commonest female cancer disease of ageing, 75% > 50y 90% sporadic, 10% hereditary lung > breast cancer mortality worries: death, sex, fertility
cumulative lifetime risk (by age 85) = 1 in 10 (incidence, not dying) age 30 age 40 age 50 age 60 10y risk 10y risk 10y risk 10y risk = = = = 1 in 250 1 in 77 1 in 43 1 in 38
Breast MRI
unifocal cancer
multifocal cancer
mastectomy
FIGURE 15.2
mastectomy and
Months
Back to Contents
diagnosed age 28 WLE + axillary clearance completion mastectomy chemo x 8 cycles chest wall / SCF RT endocrine therapy goserelin delayed reconstruction to come nipple reconstruction symmetrisation? fertility issues
RR
1.3 2.5 2.5 >4 5 10 7 10
family history
2 relatives average age <40 1 relative <50, Ashkenazi ancestry BRCA 1 or 2 gene mutation
precursor lesions
LCIS DCIS
RISK GROUPS
BREAST CANCER
invasive early breast cancer noninvasive disease (DCIS, LCIS) surgery for risk reduction
A T
P value 0.005
1
2540 2516
5
2014 1932
6
830 774
2448 2398
- anastrazole or exemestane extended adjuvant (after 5y) for further 3 y neo-adjuvant AI therapy - letrozole
HERCEPTIN
20% of invasive cancers HER-2 positive tend to be more aggressive, ER-ve tumours Herceptin well established in metastatic role given after completion of chemotherapy 3-weekly IV infusion, 19K / year cardiac function monitoring
Increase in risk of breast cancer RR = 2.0 with combined HRT RR = 1.3 with oestrogen-only HRT RR = 1.45 with tibolone no difference with route of administration risk declines after stopping HRT and by 5y reaches same level as for never taken
cyst aspiration
benign lump
lumpectomy
Peri-ductal mastitis
inverted nipple
accessory nipple